Theriva Biologics, Inc.
TOVX
$1.42
$0.00780.55%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.29% | -5.35% | -22.75% | -12.18% | -21.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.23% | -23.53% | -12.86% | 4.13% | 12.48% |
| Operating Income | 25.23% | 23.53% | 12.86% | -4.13% | -12.48% |
| Income Before Tax | 24.74% | -101.72% | -52.78% | -7.43% | 15.62% |
| Income Tax Expenses | -- | -- | -- | -- | 24.01% |
| Earnings from Continuing Operations | 18.92% | -133.91% | -63.57% | -15.34% | 14.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.92% | -133.91% | -63.57% | -15.34% | 14.90% |
| EBIT | 25.23% | 23.53% | 12.86% | -4.13% | -12.48% |
| EBITDA | 25.19% | 23.68% | 13.05% | -4.02% | -12.27% |
| EPS Basic | 80.17% | -40.57% | -27.92% | -1.73% | 21.35% |
| Normalized Basic EPS | 81.29% | 52.54% | 29.41% | 5.25% | -4.79% |
| EPS Diluted | 80.17% | -40.57% | -27.92% | -1.73% | 21.35% |
| Normalized Diluted EPS | 81.29% | 52.54% | 29.41% | 5.25% | -4.79% |
| Average Basic Shares Outstanding | 308.92% | 66.41% | 27.88% | 13.37% | 8.22% |
| Average Diluted Shares Outstanding | 308.92% | 66.41% | 27.88% | 13.37% | 8.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |